By Ed Miseta, Chief Editor, Clinical Leader
Follow Me On Twitter @EdClinical
COVID-19 has created a public that is more educated than ever before on vaccine development and the need for clinical research. That’s why Ken Getz was so surprised to learn that, according to his organization’s research, the pandemic did not have a measurable impact on the attitudes and perceptions that patients have about clinical trials.
"We saw high ratings in terms of the quality of patients’ experiences in clinical research along with a high willingness to repeat participation,” says Getz, the founder and board chair of the Center for Information and Study on Clinical Research Participation (CISCRP). However, despite the industry shift toward patient-centric practices, “the fundamental measures around the burdens of participation and their influence on the decision to participate only changed slightly.”